The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Erlander Mark since 2016.
This trader's CIK number is 1651537.
At the time of last reporting, Erlander Mark was the Chief Executive Officer of Cardiff Oncology, Inc.. (stock ticker symbol CRDF).
Also see all insider trading activities at Cardiff Oncology, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | CRDF | 10,000 | $14,300 | 0 | $0 | 0 | $0 |
| 2021 | CRDF | 965 | $9,980 | 0 | $0 | 260 | $0 |
| 2020 | CRDF | 6,993 | $9,999 | 0 | $0 | 1,511 | $0 |
| 2019 | CRDF | 0 | $0 | 0 | $0 | 12,813 | $0 |
| 2018 | CRDF | 0 | $0 | 0 | $0 | 116,250 | $0 |
| 2017 | CRDF | 0 | $0 | 0 | $0 | 80,001 | $0 |
| 2016 | CRDF | 5,000 | $10,375 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-11-25 | CRDF | Buy | 10,000 | 1.43 | 14,300 |
| 2021-03-23 | CRDF | Buy | 965 | 10.34 | 9,980 |
| 2021-01-02 | CRDF | Option Ex | 260 | .00 | 0 |
| 2020-05-14 | CRDF | Buy | 6,993 | 1.43 | 9,999 |
| 2020-01-02 | TROV | Option Ex | 261 | .00 | 0 |
| 2020-01-01 | TROV | Option Ex | 1,250 | .00 | 0 |
| 2019-10-01 | TROV | Option Ex | 1,250 | .00 | 0 |
| 2019-07-01 | TROV | Option Ex | 1,250 | .00 | 0 |
| 2019-04-01 | TROV | Option Ex | 1,250 | .00 | 0 |
| 2019-01-02 | TROV | Option Ex | 1,563 | .00 | 0 |
| 2019-01-01 | TROV | Option Ex | 7,500 | .00 | 0 |
| 2018-10-01 | TROV | Option Ex | 7,500 | .00 | 0 |
| 2018-01-30 | TROV | Option Ex | 90,000 | .00 | 0 |
| 2018-01-02 | TROV | Option Ex | 18,750 | .00 | 0 |
| 2017-09-02 | TROV | Option Ex | 30,001 | .00 | 0 |
| 2017-01-02 | TROV | Option Ex | 50,000 | .00 | 0 |
| 2016-12-14 | TROV | Buy | 5,000 | 2.08 | 10,375 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Erlander Mark (Chief Executive Officer of Cardiff Oncology, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.